Kornimate/medical-research-clean huggingface dataset:
red blood cell transfusion in the ambulatory setting: impact on home functional status

Conditions: Red Blood Cell Transfusions; Anemia; Hematology; Oncology; Ambulatory Care

Summary: do ambulatory rbc transfusions improve home functional status?

background: red blood cell (rbc) transfusion is frequently employed in both ambulatory and hospital environments with the aim of improving patient functional status. the efficacy of this 10.5 billion dollar per year practice however has been increasingly called into question. the investigators propose to directly measure the impact of outpatient rbc transfusions on at-home functional status by recording several physiological parameters and quantifiable physical activity metrics, e.g. daily energy expenditure and daily total step count, using the actigraph wgt3x-bt. this device is an accelerometer-based wearable similar in size to a small watch and is worn at the waist. study participants will wear the device during the course of their daily activities giving the investigators quantifiable insight into activity levels in the home environment. methods/design: this will be a randomized crossover pilot clinical trial with participant study duration of 28 days. the crossover nature allows each patient to serve as his/her own control. details of the study design are provided in the text. briefly, patients presenting at mayo clinic scottsdale's ambulatory infusion center (aic) will be randomized to one of two arms: 1) receive an rbc transfusion as scheduled (transfuse), or 2) abstain from the scheduled transfusion (no-transfuse). after an appropriate washout period, patients will cross from the transfuse arm to the no-transfuse arm or vice-versa. activity levels will be recorded continuously throughout the study with no need for intervention by the patient. in addition to device data, survey data will be collected via a weekly telephone interview. the primary outcome measures will include both technical performance metrics such as daily energy expenditure as well as practical performance metrics such as changes in step count. a variety of secondary outcome measures include daily sedentary time and promis global 10 scores. discussion: this trial will directly assess the impact of red blood cell transfusion on patient functional status in the location most important - the home. patient recruitment will begin in august 2016 and is due to be completed in august 2017.

Eligibility criteria:
inclusion criteria: * age \> 18 years * at least on prior encounter in the aic * planned rbc transfusion exclusion criteria: * refusal to provide informed consent * refusal by the health care team * acute ischemia (e.g. mi, cva) * hemoglobin \< 7.0 g/dl * active bleeding * symptomatic anemia (hypotension, tachycardia, angina, syncope/pre-syncope believed related to anemia * non-ambulatory functional status * established or uncertain pregnancy status
development and standardization methods

Conditions: Androgenetic Alopecia

Summary: the objective of this study is to establish a standardized methodology that integrates various parameters to comprehensively assess and evaluate hair growth and scalp health.

a total of 25 participants, consisting of 13 males and 12 females who have complaints of androgenetic alopecia (aga) will be enrolled. this research seeks to develop and implement a robust and standardized approach that incorporates a diverse range of parameters. these parameters include: * measurement of hair regrowth from aga-affected area. * number of new hairs from the aga-affected area and tattoo area. * evaluation of hair strength through tensile testing. * assessment of hair length * global picture of head crown * quantitative analysis of scalp keratin levels. * visual documentation and quantitative scoring of baldness using the norwood-hamilton and ludwig scales and its inter-variability.

Eligibility criteria:
inclusion criteria: 1. age between 18 and 55 years (both inclusive). 2. good general health as determined from recent medical history. 3. no previous history of adverse skin conditions, and not under any medication likely to interfere with the results. 4. patient having androgenic alopecia condition with grade of 1 to 3 (dermatological assessment) exclusion criteria: 1. recent hair transplantation or other surgical interventions on the scalp within the past year. 2. pregnant or breastfeeding women will be excluded due to potential hormonal influences on hair growth. 3. history of cancer treatment involving chemotherapy or radiotherapy to the scalp. 4. presence of significant dermatological conditions affecting the scalp other than androgenetic alopecia (e.g., psoriasis, severe seborrheic dermatitis). 5. history of major systemic diseases (e.g., uncontrolled diabetes, severe cardiovascular diseases, autoimmune disorders). 6. any other condition which could warrant exclusion from the study, as per the dermatologist/investigator's discretion.
pseudomonas aeruginosa infections among covid-19 patients in intensive care units at chru of nancy (pyo-covid-3)

Conditions: Pseudomonas Aeruginosa; COVID-19

Summary: p. aeruginosa is an opportunistic bacterium known to be responsible for numerous healthcare-associated infections, particularly in intensive care units (icu). the frequency of these infections seems to have increased during the first waves of the covid-19 pandemic. identifying cases of co-infection and secondary infections with p. aeruginosa in patients with covid-19 would provide a better understanding of the epidemiological evolution and characteristics of infected patients. treatment of p. aeruginosa infections requires the use of antibiotics. antibiotic resistance is a growing problem, with an increase in resistance among p. aeruginosa strains. the misuse of antibiotics to treat patients can accentuate the phenomenon of antibiotic resistance, and failure to take account of resistance revealed by antibiograms can compromise patient recovery. analysis of bacteriological results and patient medical records would enable a posteriori evaluation of the proper use of antibiotics (choice and adaptation of molecules, doses and duration of prescriptions), and identify any areas for improvement. the main objective is to describe the evolution of p. aeruginosa infections in icu patients with covid-19 during the first 3 waves of covid-19 (01/03/2020 to 31/05/2021). secondary objectives are to describe the typology of p. aeruginosa strains identified among included patients (sampling sites and resistance profiles), to assess antibiotic prescriptions for these patients and to describe the relapse rate of included patients with a first p. aeruginosa infection.


Eligibility criteria:
inclusion criteria: * adult patients hospitalized for at least 48 h in an intensive care unit (icu) at chru-nancy for acute respiratory distress syndrome due to covid-19. * patients hospitalized from 1st march 2020 to 31st may 2021. * patient developed an hospital-acquired infection caused by p. aeruginosa during their icu stay. exclusion criteria: * patients \<18 years old. * patient without covid-19 at the icu admission. * patients with p. aeruginosa isolated \<48 hours following icu admission. * patients who did not want to be included in the study.

Keywords: icu infections antimicrobial resistance
biomarkers for invasive mucormycosis

Conditions: Mucorales Infection; Mucormycosis

Summary: mucormycosis (mm) is one of the main invasive fungal infection (ifi), and is determined by filamentous fungi belonging to the order of mucorales, with a mortality rate ranging from 20 to 60% according to localization. prompt initiation of adequate antifungal therapy is critical for treating mucormycosis. early diagnostic is therefore essential. the presence in the mucorales' cell wall of uncommon monosaccharides open interesting perspectives for the development of specific diagnostic biomarkers. this study evaluate a diagnostic test for mucormycosis in a cohort of patients with mm and in control groups (high-risk patients without mm and patients with another ifi).


Eligibility criteria:
inclusion criteria: * men and women * age : children and adults from 3 to 64 years old (18 to 64 for controls) * in patients whose consent has been collected after information. in the case of children, information on the study will be given to the holders of parental authority and then to the child to obtain their consent. * patient social insured * specific medical conditions : 1. for the case group : any patient hospitalized in one of the departments of the university hospital of lille, in which the diagnosis of mucormycosis was conducted on the following criteria: * conventional mycology data and / or * positivity of q-prc and / or * anatomopathologic diagnosis associated with a compatible clinical situation 2. for the control group 1 patient assessed for hematopoietic stem cell transplantation, considered at risk for ifi but for whom the pre-transplantation review will have excluded an ongoing infection 3. for control group 2 any patient hospitalized in a department of lille university hospital, in which the diagnosis of disseminated candidiasis or invasive pulmonary aspergillosis has been made according to specific classifications (eortc/msg criteria, aspicu criteria) exclusion criteria: * patients for whom the inclusion criteria are not met * co-infection mucormycosis/other ifi

Keywords: mucormycosis invasive fungal infection cell wall oligo/polysaccharides biomarkers
narrow band imaging (nbi) under electronic bronchoscope in lung cancer

Conditions: Lung Cancer; Malignant Airway Obstruction

Summary: narrow-band imaging (nbi) is useful to better demarcate the superficial extent of central type of lung cancer, but its sensitivity and specificity in clinical practice were little studied. this study aimed to investigate the diagnostic effects of nbi in suspected patients with central lung cancer and its application in staging diagnosis of central lung cancer.

with high morbidity and mortality, lung cancer is one of the most common tumors in the world. therefore, early detection, accurate diagnosis and staging division can effectively guide clinical interventions, thereby improving patient survival. narrowband imaging under electronic bronchoscope (nbi) is an emerging optical image emphasis technology that can enhance the contrast between the mucosal surface and underlying blood vessels, specifically display the distribution of blood vessels, and highlight the subtle changes in mucosal structure. meanwhile, it can reduce unnecessary biopsy with low risk and costs. in recent years, nbi technology has gradually begun to show its unique advantages in the diagnosis of gastric cancer, esophageal cancer, nasopharyngeal cancer, and bladder cancer. the purpose of this study is to explore the diagnostic value of nbi under electronic bronchoscopy for early detection and accurate diagnosis of lung cancer, and to provide a more economical, safer and more efficient diagnosis option for lung cancer patients.

Eligibility criteria:
inclusion criteria: - patients had a history or current central lung cancer exclusion criteria: - none
motivations for weight loss

Conditions: Obesity

Summary: this study tests the effects of emphasizing different motivations for wanting to lose weight on weight loss maintenance in women. at the start of the study, participants will be weighed and will complete questionnaires about their health, weight history, eating and exercise habits, body satisfaction and mood. participants will then be randomly assigned to 1 of 4 treatments. participants in all 4 groups will receive information on topics related to eating and exercise, and will receive calorie and fat intake goals, and exercise goals. the 4 treatments will differ in the emphasis given to various reasons for wanting to lose weight. at 6, 12 and 18 months after enrollment, participants will again have weights measured and fill out questionnaires.


Eligibility criteria:
inclusion criteria: * body mass index greater than or equal to 27 and less than or equal to 35 * rating both physical appearance and health concerns as important motivations for weight loss * successful completion of a food and exercise diary over a 5-day period

Keywords: overweight
personalized variable versus fixed dose glucocorticoid therapy in aecopd

Conditions: Chronic Obstructive Pulmonary Disease

Summary: the hypothesis is that in acute exacerbated chronic obstructive pulmonary disease (aecopd), personalized variable dose glucocorticoid treatment will result in superior clinical outcome when compared to fixed dose therapy.

treatment with glucocorticoid for acute exacerbations of copd results in the improvement of clinical outcomes. however, the optimal doses of glucocorticoid for each individual patient has not been determined. according to gold report 2014, a dose of 40 mg prednisone per day for 5 days is recommended (evidence b), although there are insufficient data to provide firm conclusions concerning the optimal duration of corticosteroid therapy of acute exacerbations of copd. the purpose of the current study is to compare clinical outcomes of personalized or fixed dose of glucocorticoid in patients with acute exacerbations of copd.

Eligibility criteria:
inclusion criteria: * exacerbation of copd as defined by the presence of at least 2 of the following: change in baseline dyspnea, cough, or sputum quantity or purulence. exclusion criteria: * signs of severe exacerbation (arterial ph \ 9.3 kpa) * history of asthma * significant or unstable co-morbidity * participated in another study 4 weeks before admission * previously randomized to this study * known hypersensitivity to prednisolone * inability to give written informed consent * radiological diagnosis of pneumonia * estimated survival of less than 6 months due to severe comorbidity * use of glucocorticoid within 1 month before admission

Keywords: acute exacerbations corticosteroids chronic obstructive pulmonary disease doses
pharmacokinetics of lcz696 in subjects with mild and moderate renal impairment compared to healthy subjects with normal renal function

Conditions: Mild and Moderate Renal Impairment

Summary: the purpose of this study is to determine the multiple dose pharmacokinetics of lcz696 and its metabolites in subjects with mild to moderate renal impairment and to evaluate the safety of lcz696 in this population.


Eligibility criteria:
inclusion criteria: 1. male, and female subjects of non-child bearing potential, 2. subjects were to weigh at least 50 kg to participate in the study, 3. and body mass index \< 40 kg/m2 4. subjects were able to communicate well with the investigator, to understand and comply with the requirements of the study; 5. subjects were able to understand and sign the written informed consent; for renal insufficient subjects: 1. stable renal disease without evidence of renal progressive * mild renal function: calculated crcl of 50-≤80 ml/min * moderate renal function: calculated crcl of 30-\<50 ml/min 2. vital signs: * oral body temperature between 35.0-37.8 °c * systolic blood pressure, 95-180 mm hg * diastolic blood pressure, 60-110 mm hg * pulse rate, 54-95 bpm for healthy subjects only 1. a serum creatinine with a calculated crcl of \>80 ml/min 2. vital signs: * oral body temperature between 35.0-37.2 °c * systolic blood pressure, 95-140 mm hg * diastolic blood pressure, 60-100 mm hg * pulse rate, 45-90 bpm exclusion criteria: 1. current use of ace inhibitors, valsartan, and drugs that were known as cyp2c9 substrates, potassium-sparing diuretics; 2. smokers; 3. history of renal transplant at any time in the past and on immunosuppressant therapy; 4. dialysis patients; 5. medical history of clinically significant ecg abnormalities or a family history of a prolonged qt-interval syndrome; 6. any surgical or medical condition which may significantly alter the absorption, distribution, metabolism or excretion of any drug substance; other protocol defined inclusion/exclusion criteria may apply

Keywords: renal impairment, lcz696
novel treatment for pusher syndrome using physical therapy

Conditions: Pusher Syndrome

Summary: the purpose of this study is to see if a specific physical therapy intervention speeds recovery from stroke-related "pusher syndrome."


Eligibility criteria:
inclusion criteria: * recent (within 2 months) unilateral stroke * burke lateropulsion scale ≥ 2 * age 21 to 89 years * ability to provide informed consent * english-speaking exclusion criteria: * prior stroke within the past 6 months * cerebellar stroke * stroke-related brain imaging (mri or ct) unavailable * global or receptive aphasia * prior documented neurologic disorder (e.g., multiple sclerosis, parkinson's)

Keywords: stroke pusher syndrome contraversive pushing lateropulsion rehabilitation physical therapy
study of temporomandibular joint dysfunction

Conditions: Diseases of the Temporomandibular Joint

Summary: given the frequency of temporomandibular joint (tmj) dysfunction and the variations in its expression, this project intends to initiate a process of objective evaluation of mandible function and its impairment due to different diseases. the first step is to determine whether 3d kinematic quantification of the mandible would make it possible to objectively assess the effect of post-operative management on tmj function recovery. if the first results are encouraging and show the sensitivity of the analysis of minor joint dysfunctions, the investigators will evaluate the feasibility of kinematic assessments for major tmj dysfunctions and for the follow-up of patients. the expected benefits of this study are to be considered in the medium term and concern the possibilities offered by measuring mandible kinetics in the treatment of tmj disorders.


Eligibility criteria:
inclusion criteria: patients: * patients who have provided verbal consent, * patients over 18 years old, * patients with mandible dentition compatible with placement of the kinetic measurement device, * patients with a tmj disease requiring surgery (irreducible dislocation of the joint disc, damage to the joint disc requiring discectomy, ankylosis or severe arthritis of the mandible requiring mandible implants or a tmj prosthesis). asymptomatic subjects: * subjects who have provided verbal consent, * subjects over 18 years old, * subjects with class 1 occlusion, * subjects without dental implants, * subjects with no history of joint dysfunction, * absence of clicking, popping, or grating sounds during large movements and during palpation of the tmj with the mouth slightly open (distance between incisors around 1 cm) * absence of headache, * absence of tinnitus, * kinematic curves around the mean. exclusion criteria: * adults under guardianship, * patients without national health insurance cover.
a retrospective cohort study of 15 cases of pelvic fractures complicated by morel-lavallee lesion

Conditions: Pelvic Fracture; Morel-Lavallee Lesion

Summary: some related factors of pelvic fracture and morel-lavallee injury (mll) are preliminarily discussed, which provides some preliminary references for early clinical detection and research of such injuries.

inclusion criteria: (1) the clinical symptoms are consistent with the diagnosis of pelvic fracture, and the diagnosis is confirmed by imaging, including emergency or sub-emergency ct data within 72 hours after injury. (2) the symptoms of the diagnosis of mll were pain and swelling at the site of occurrence, a sense of soft tissue fluctuation found on physical examination, and a complete process of puncture drainage + negative pressure suction therapy. (3) the patients and their families have given informed consent to this study and signed the informed consent form, which meets the ethical requirements. exclusion criteria: (1) incomplete imaging data, especially the lack of emergency or sub-emergency ct data within 72 hours after injury. (2) cases of other severe lower limb fractures such as femur and trochanter, and lower limb fractures combined with mll injury have been reported in the literature.

Eligibility criteria:
inclusion criteria: * (1) the clinical symptoms are consistent with the diagnosis of pelvic fracture, and the diagnosis is confirmed by imaging, including emergency or sub-emergency ct data within 72 hours after injury. (2) the symptoms of the diagnosis of mll were pain and swelling at the site of occurrence, a sense of soft tissue fluctuation found on physical examination, and a complete process of puncture drainage + negative pressure suction therapy. (3) the patients and their families have given informed consent to this study and signed the informed consent form, which meets the ethical requirements. exclusion criteria: * (1) incomplete imaging data, especially the lack of emergency or sub-emergency ct data within 72 hours after injury. (2) cases of other severe lower limb fractures such as femur and trochanter, and lower limb fractures combined with mll injury have been reported in the literature.

Keywords: morel-lavallee lesion pelvic fracture
early detection of cardiac damage with cmr in women with breast cancer

Conditions: Cardiotoxicity; Breast Cancer; Chemotherapy Induced Systolic Dysfunction

Summary: with this study the investigators will assess early cardiac damage by means of global longitudinal strain (gls) in newly diagnosed breast cancer (bc) patients treated with anthracycline-based chemotherapy, and to investigate whether myocardial damage as measured with t1 / t2 cardiovascular magnetic resonance (cmr) mapping and plasma hs-troponin t is related to changes in gls.


Eligibility criteria:
inclusion criteria: * female * age ≥ 18 years * a diagnosis of primary breast cancer * starting (neo-) adjuvant chemotherapy treatment within 2 months after screening * cardiotoxicity risk score of intermediate, high or very high risk exclusion criteria: * previous radiotherapy or systemic cancer treatment * cancer metastasis * life expectancy of less than 6 months * history of myocardial infarction or heart failure * known contra-indications for cmr * refusal or inability to provide informed consent
a national screening program for islet autoantibodies among first-degree relatives of t1d patients

Conditions: Type 1 Diabetes; Autoantibodies Screening

Summary: a national screening program for the presence of islet autoantibodies (ia) in relatives of people with type 1 diabetes (pwt1d) aiming at identifying people with pre-clinical (stage 1 \& 2) t1d and dka prevention on the clinical presentation of t1d. all participants will be screened at study entry for the presence of 4 islet autoantibodies: glutamic acid decarboxylase antibody (gada), insulinoma-associated-2 antibody (ia-2a), insulin antibodies (iaa) and zinc transporter-8 antibodies (znt8a). the adap assay will be used to detect ia. a confirmation blood sample for positive participants with two or more ia will be taken. the confirmation analysis will be done by the adap assay, conventional elisa, and ria. participants identified as part of the study with pre-symptomatic type 1 diabetes (t1d) (stages 1 and 2) will be referred to complete an educational program emphasizing dka prevention as part of routine medical care .during the study, cases of stage 2 and stage 3 diabetes and dka events in participants who are positive for ia will be documented.


Eligibility criteria:
inclusion criteria: * age 2-45 years * first-degree relatives of type 1 diabetes probands * signing an informed consent exclusion criteria: * known diabetes of any kind (type 1, type 2, mody) * have a previous history of being treated with insulin or oral diabetes medications. * currently, using systemic immunosuppressive agents (topical and inhaled agents are acceptable)